## MOH: Molina Healthcare Inc - XLV: Healthcare

### Executive Summary

No thesis match: PEG 2.62 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($148.88)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bearish (Bullish: 0, Bearish: 1)

**1. Bronstein, Gewirtz & Grossman, LLC Is Investigating Molina Healthcare, Inc. (MOH) And Encourages Stockholders to Connect**
- Source: WPRI.com | 20251214T160823 | Somewhat-Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Molina Healthcare, Inc. (MOH) on behalf of investors who purchased securities before February 5, 2025, and still hold them. The investigation focuses on whether Molina, its officers, and/or directors engaged in corporate wrongdoing. The firm encourages affected stockholders to contact them to assist with the investigation.

**2. Bronstein, Gewirtz & Grossman, LLC Is Investigating Molina Healthcare, Inc. (MOH) And Encourages Stockholders to Connect**
- Source: MyStateline | 20251214T160820 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Molina Healthcare, Inc. (MOH) for corporate wrongdoing involving its officers and/or directors. The firm encourages stockholders who purchased Molina securities before February 5, 2025, and still hold them, to contact them to assist with the investigation. This investigation operates on a contingency fee basis with no direct cost to the stockholders.

**3. Molina Healthcare (MOH): Buy, Sell, or Hold Post Q3 Earnings?**
- Source: Finviz | 20251215T230300 | Neutral | Relevance: 99%
- Molina Healthcare (MOH) has seen a significant stock drop of 42.1% in the last six months, prompting questions about its future. Despite recent softer quarterly results, the company exhibits strong long-term revenue growth and benefits from economies of scale. However, weak customer growth signals potential challenges, leading to a debate on whether MOH presents a buying opportunity after its decline.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 8 ($0.44M) |
| Sells | 1 ($0.05M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 61.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.1%)
- Capital World Invest: 9.5% (-2.0%)
- Blackrock Inc.: 8.4% (-3.9%)
- Price (T.Rowe) Assoc: 6.5% (+58.8%)
- AQR Capital Manageme: 5.4% (+217.0%)

### Key Risks

1. Valuation risk: PEG 2.6x with declining EPS estimates leaves no margin for error.
2. Elevated short interest (11.4%): bears positioning against stock.
3. Long-term trend broken: trading 30.8% below SMA200.
4. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.62 signals overvaluation risk, limited margin of safety. Forward P/E 9.8x attractive for 18% earnings growth. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $8.7B |
| Beta | 0.52 |
| 52W Range | $133.40 - $359.97 |
| Short Interest | 11.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.62 |
| Forward P/E | 9.8 |
| Current P/E | 11.6 |
| YoY Growth | 18.1% |
| EPS Direction | FALLING |

### Technicals

MRS_20 weakening modestly (-1.0% over 5 days). Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 89th percentile. MRS_5 (-1.4%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 6.5% shows strong absolute momentum above own 20MA. Outperforming sector by 6.7pp, stock-specific strength. Below SMA200 (0.69x), long-term trend not supportive. MACD histogram positive (2.87), confirming momentum. RSI neutral at 56. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 6.64% (CS: 90) | Strong |
| RSI_14 | 56.2 | Neutral |
| MACD Histogram | 2.87 | Bullish |
| vs SMA20 | 1.065x | Above |
| vs SMA50 | 0.996x | Below |
| vs SMA200 | 0.692x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $160.88
- **Stop Loss:** $148.88 (7.5% risk)
- **Target:** $172.88 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 83
- **Position Value:** $13,353.04
- **Portfolio %:** 13.35%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-02-04 (Est: $0.64)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.89 | $1.84 | -52.7% |
| 2025Q2 | $5.53 | $5.48 | -0.9% |
| 2025Q1 | $5.96 | $6.08 | +2.0% |
| 2024Q4 | $5.88 | $5.05 | -14.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*